BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 26638886)

  • 1. S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway.
    Lu Z; Zhou R; Kong Y; Wang J; Xia W; Guo J; Liu J; Sun H; Liu K; Yang J; Mi M; Xu H
    Curr Cancer Drug Targets; 2016; 16(5):455-65. PubMed ID: 26638886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
    Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
    Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.
    Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ
    Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
    Li Y; Wang Z; Kong D; Li R; Sarkar SH; Sarkar FH
    J Biol Chem; 2008 Oct; 283(41):27707-27716. PubMed ID: 18687691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
    Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
    Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.
    Das TP; Suman S; Alatassi H; Ankem MK; Damodaran C
    Cell Death Dis; 2016 Feb; 7(2):e2111. PubMed ID: 26913603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
    Yang ZP; Zhao Y; Huang F; Chen J; Yao YH; Li J; Wu XN
    World J Gastroenterol; 2015 Sep; 21(36):10385-99. PubMed ID: 26420965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
    Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
    Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.
    Li F; Dong X; Lin P; Jiang J
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29360760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways.
    Ock CW; Kim GD
    Molecules; 2021 Nov; 26(21):. PubMed ID: 34771123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways.
    Lu Z; Lu C; Li C; Jiao Y; Li Y; Zhang G
    Mol Med Rep; 2019 Sep; 20(3):2091-2100. PubMed ID: 31322237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
    Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnolin inhibits prostate cancer cell growth in vitro and in vivo.
    Huang Y; Zou X; Zhang X; Wang F; Zhu W; Zhang G; Xiao J; Chen M
    Biomed Pharmacother; 2017 Mar; 87():714-720. PubMed ID: 28092770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
    Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
    J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
    Shukla S; Bhaskaran N; Babcook MA; Fu P; Maclennan GT; Gupta S
    Carcinogenesis; 2014 Feb; 35(2):452-60. PubMed ID: 24067903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycotoxin verrucarin A inhibits proliferation and induces apoptosis in prostate cancer cells by inhibiting prosurvival Akt/NF-kB/mTOR signaling.
    Liu Y; Gao X; Deeb D; Zhang Y; Shaw J; Valeriote FA; Gautam SC
    J Exp Ther Oncol; 2016 Nov; 11(4):251-260. PubMed ID: 27849335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro.
    Hedlund TE; Johannes WU; Miller GJ
    Prostate; 2003 Jan; 54(1):68-78. PubMed ID: 12481257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
    Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
    Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.